Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C125899
http://purl.obolibrary.org/obo/NCIT_C125899
Preferred Name

Dalpiciclib
Definitions
A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.
prefLabel
Dalpiciclib
label
Dalpiciclib
NCI_META_CUI
CL504548
PDQ_Closed_Trial_Search_ID
778742
code
C125899
prefixIRI
NCIT:C125899
in_subset
Preferred_Name
Dalpiciclib
FDA_UNII_Code
5ZHA5P4PFX
Contributing_Source
FDA
Maps_To
CDK4/6 Inhibitor SHR6390
CAS_Registry
1637781-04-4
NCI_Drug_Dictionary_ID
778742
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
778742
Semantic_Type
Pharmacologic Substance
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display